Form 4: CorMedix CLO Zelnick Kaufman Gains 36,006 Shares

CorMedix Inc.'s Chief Legal Officer, Beth Zelnick Kaufman, acquired 36,006 shares of common stock through the vesting of performance stock units.

Summary

• Beth Zelnick Kaufman, Chief Legal Officer of CorMedix Inc., acquired 36,006 shares of common stock.
• The acquisition occurred on February 4, 2026, at a price of $0.00 per share.
• These shares represent the achievement of performance stock units (PSUs) granted on January 2, 2025.
• The Compensation Committee determined that performance conditions for the first of three performance periods were met.
• The PSUs are still subject to time-based vesting conditions.
• Following this transaction, Ms. Zelnick Kaufman beneficially owns 269,108 shares of CorMedix common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates an executive has met performance targets, leading to increased insider ownership and alignment with shareholder interests, without any negative implications.

Positives

• The Chief Legal Officer achieved performance conditions for a portion of her performance stock units, indicating successful execution against company goals.
• Increased insider ownership aligns management interests with shareholder interests.

Future Outlook

The remaining performance stock units are subject to further time-based vesting conditions, implying continued alignment of executive compensation with future company performance.

Industry Context

StockSavvy.ai notes that the vesting of performance-based equity awards is a common practice in executive compensation across industries, designed to incentivize executives to meet specific operational or financial targets. This particular filing indicates that CorMedix's compensation structure is functioning as intended to reward performance.

Stakeholder Impact

• Shareholders: Potentially positive, as it signals management's achievement of performance goals and increased alignment through equity ownership.
• Employees: May indicate a healthy compensation structure that rewards performance.

Next Steps

• The acquired PSUs are subject to further time-based vesting conditions.
• Future performance periods for the PSUs will be evaluated by the Compensation Committee.

Key Dates

Keywords

CorMedix, CRMD, Beth Zelnick Kaufman, insider transaction, Form 4, performance stock units, PSU, equity compensation, beneficial ownership, Chief Legal Officer